6sqd
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Crystal structure of M. tuberculosis InhA in complex with NAD+ and 2-pyrazol-1-ylbenzoic acid== | ==Crystal structure of M. tuberculosis InhA in complex with NAD+ and 2-pyrazol-1-ylbenzoic acid== | ||
| - | <StructureSection load='6sqd' size='340' side='right'caption='[[6sqd]]' scene=''> | + | <StructureSection load='6sqd' size='340' side='right'caption='[[6sqd]], [[Resolution|resolution]] 1.72Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6SQD OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6SQD FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6sqd]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Myctu Myctu]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6SQD OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6SQD FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6sqd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6sqd OCA], [http://pdbe.org/6sqd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6sqd RCSB], [http://www.ebi.ac.uk/pdbsum/6sqd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6sqd ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=LT8:2-pyrazol-1-ylbenzoic+acid'>LT8</scene>, <scene name='pdbligand=NAD:NICOTINAMIDE-ADENINE-DINUCLEOTIDE'>NAD</scene></td></tr> |
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">inhA, Rv1484, MTCY277.05 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=83332 MYCTU])</td></tr> | ||
| + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Enoyl-[acyl-carrier-protein]_reductase_(NADH) Enoyl-[acyl-carrier-protein] reductase (NADH)], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.3.1.9 1.3.1.9] </span></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6sqd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6sqd OCA], [http://pdbe.org/6sqd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6sqd RCSB], [http://www.ebi.ac.uk/pdbsum/6sqd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6sqd ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Tuberculosis (TB) remains a leading cause of mortality among infectious diseases worldwide. InhA has been the focus of numerous drug discovery efforts as this is the target of the first line pro-drug isoniazid. However, with resistance to this drug becoming more common, the aim has been to find new clinical candidates that directly inhibit this enzyme and that do not require activation by the catalase peroxidase KatG, thus circumventing the majority of the resistance mechanisms. In this work, the screening and validation of a fragment library are described, and the development of the fragment hits using a fragment growing strategy was employed, which led to the development of InhA inhibitors with affinities of up to 250 nM. | ||
| + | |||
| + | Fragment-Based Design of Mycobacterium tuberculosis InhA Inhibitors.,Sabbah M, Mendes V, Vistal RG, Dias DMG, Zahorszka M, Mikusova K, Kordulakova J, Coyne AG, Blundell TL, Abell C J Med Chem. 2020 Apr 15. doi: 10.1021/acs.jmedchem.0c00007. PMID:32240584<ref>PMID:32240584</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6sqd" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Abell C]] | + | [[Category: Myctu]] |
| - | [[Category: Blundell | + | [[Category: Abell, C]] |
| - | [[Category: Coyne | + | [[Category: Blundell, T L]] |
| - | [[Category: Mendes V]] | + | [[Category: Coyne, A G]] |
| - | [[Category: Sabbah M]] | + | [[Category: Mendes, V]] |
| + | [[Category: Sabbah, M]] | ||
| + | [[Category: Inha]] | ||
| + | [[Category: Oxidoreductase]] | ||
Revision as of 07:05, 29 April 2020
Crystal structure of M. tuberculosis InhA in complex with NAD+ and 2-pyrazol-1-ylbenzoic acid
| |||||||||||
Categories: Large Structures | Myctu | Abell, C | Blundell, T L | Coyne, A G | Mendes, V | Sabbah, M | Inha | Oxidoreductase
